COMPANY PROFILE

Lung Therapeutics

Explore full profile

Pursues innovative treatments for underserved, life-threatening lung conditions

Austin, United StatesFounded 2013Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2019

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Lung Therapeutics

Lung Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for orphan pulmonary diseases and fibrosis. The company operates in the biopharmaceutical market, targeting conditions with significant unmet medical needs. Its primary clients include healthcare providers, hospitals, and research institutions that treat patients with severe lung conditions. Lung Therapeutics employs a business model centered around research and development, advancing its drug candidates through clinical trials to achieve regulatory approval. The company generates revenue through funding rounds, including Series B and Series C financing, which support the progression of its clinical pipeline. Lung Therapeutics aims to bring innovative treatments to market, addressing critical gaps in pulmonary care.

Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2013
Headquarters: Austin, United States
Employees: 8
Open positions: None listed
Dealroom signal: 62.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Oct 2023
Capital deployed: $18M
Preferred round: PRIVATE PLACEMENT VC
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Lung Therapeutics.

See all news

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Oct 2023	$0	—	Aileron Therapeutics	↗
SERIES COther financing	Jun 2019	$36M	$144M	Bios Partners	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Lung Therapeutics website traffic

Latest recorded traffic for Lung Therapeutics is 350 monthly website visits, down 79.4% over the last three months. Lung Therapeutics's team declined 65.2% over the past year.

Latest monthly visits350 3-month web change-79.4% 1-year team growth-65.2%

Monthly website visitsApr 2016–Feb 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SHShenandoahDevelopment of oncology treatment technologies	Siloam Springs, United States	Operational	—	$20M	$80M
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
ATAbdera TherapeuticsUses antibody engineering to design and develop new precision radiotherapeutics for cancer	South San Francisco, United States	Operational
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational
OMOnena MedicinesRevolutionary AI-optimized medicines delivering hope where it’s needed most	Allschwil, Switzerland	Operational
QUQualisuredxDeveloping molecular tests that enhance cancer care by identifying features that help oncologists to personalize treatments	Calgary, Canada	Operational
TTTelo TherapeuticsDeveloping a novel, personalized medicine therapeutic to selectively inhibit cancer cell immortality	San Francisco, United States	Operational
PRPreviseWorking on earlier detection and prevention of cancer, starting with esophageal cancer	Baltimore, United States	Acquired